Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/ijmr.IJMR_3215_20 http://scihub22266oqcxt.onion/10.4103/ijmr.IJMR_3215_20 33818465!8184076!33818465     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Indian+J+Med+Res 2021 ; 153 (1 & 2): 17-25 Nephropedia Template TP {{tp|p=33818465|t=2021. An overview of preclinical animal models for SARS-CoV-2 pathogenicity |pdf=|usr=}}{{33818465}} gab.com Text An overview of preclinical animal models for SARS-CoV-2 pathogenicity JO: Indian J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33818465 #FOAvip Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of fatalities globally since its origin in November 2019. The SARS-CoV-2 shares 79 and 50 per cent genome similarity with its predecessors, severe SARS-CoV and Middle East respiratory syndrome (MERS) coronavirus, all belonging to the same genus, Betacoronavirus. This relatively new virus has stymied the effective control of COVID-19 pandemic and caused huge social and economic impact worldwide. The FDA-approved drugs were re-purposed to reduce the number of fatalities caused by SARS-CoV-2. However, controversy surrounds about the efficacy of these re-purposed antiviral drugs against SARS-CoV-2.This necessitates the identification of new drug targets for SARS-CoV-2. Hence, the development of pre-clinical animal model is warranted. Such animal models may help us gain better understanding of the pathophysiology of SARS-CoV-2 infection and will be effective tools for the evaluation and licensure of therapeutic strategies against SARS-CoV-2. This review provides a summary of the attempts made till to develop a suitable animal model to understand pathophysiology and effectiveness of therapeutic agents against SARS-CoV-2. Twit Text FOAVip An overview of preclinical animal models for SARS-CoV-2 pathogenicity ????Indian J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33818465 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33818465 #FOAvip English Wikipedia <ref>{{Cite pmid|33818465}}</ref> An overview of preclinical animal models for SARS-CoV-2 pathogenicity #MMPMID33818465 Munshi I; Khandvilkar A; Chavan SM; Sachdeva G; Mahale SD; Chaudhari UK Indian J Med Res 2021[Jan]; 153 (1 & 2): 17-25 PMID33818465show ga Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of fatalities globally since its origin in November 2019. The SARS-CoV-2 shares 79 and 50 per cent genome similarity with its predecessors, severe SARS-CoV and Middle East respiratory syndrome (MERS) coronavirus, all belonging to the same genus, Betacoronavirus. This relatively new virus has stymied the effective control of COVID-19 pandemic and caused huge social and economic impact worldwide. The FDA-approved drugs were re-purposed to reduce the number of fatalities caused by SARS-CoV-2. However, controversy surrounds about the efficacy of these re-purposed antiviral drugs against SARS-CoV-2.This necessitates the identification of new drug targets for SARS-CoV-2. Hence, the development of pre-clinical animal model is warranted. Such animal models may help us gain better understanding of the pathophysiology of SARS-CoV-2 infection and will be effective tools for the evaluation and licensure of therapeutic strategies against SARS-CoV-2. This review provides a summary of the attempts made till to develop a suitable animal model to understand pathophysiology and effectiveness of therapeutic agents against SARS-CoV-2. |*Disease Models, Animal[MESH] |Animals[MESH] |COVID-19/*physiopathology[MESH] |Humans[MESH] |SARS-CoV-2/*pathogenicity[MESH]An overview of preclinical animal models for SARS-CoV-2 pathogenicity (epmc).pdf DeepDyve Pubget Overpricing